Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score

Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score

Introduction: Aromatase-inhibitors (AIs) are commonly used for treatment of patients with hormone-receptor positive breast carcinoma, and are known to induce bone density loss and increase the risk of fractures. The current standard-of-care screening tool for fracture risk is bone mineral density (B...

Full description

Bibliographic Details
Main Authors: Veronica Mariotti, David B. Page, Oksana Davydov, Didier Hans, Clifford A. Hudis, Sujata Patil, Siddharth Kunte, Monica Girotra, Azeez Farooki, Monica N. Fornier
Format: Article
Language:English
Published: Elsevier 2017-06-01
Series:Journal of Bone Oncology
Subjects:
Trabecular bone score
Breast cancer
Aromatase inhibitor
Osteoporosis
TBS
FRAX®
Fracture risk assessment tool
Osteopenia
Manitoba study
Adjuvant
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137416300707

Internet

http://www.sciencedirect.com/science/article/pii/S2212137416300707

Similar Items